Emerging treatments for major depression

Expert Review of Neurotherapeutics

Volumn 7, Issue 2, 2007, Pages 203-213

  Norman, Trevor R ^a   Burrows, Graham D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Agomelatine; Cortisol; Duloxetine; Glucocorticoid receptor; Glutamatergic receptor; HPA axis; Neuropeptide; Neurotropic hypothesis; Substance P

Indexed keywords

11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; AGOMELATINE; AMFEBUTAMONE; AMINOGLUTHEMIDE; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; APREPITANT; BENZOCYCLOBUTANE DERIVATIVE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DOPAMINE RECEPTOR STIMULATING AGENT; DULOXETINE; FLUOXETINE; GLUCOCORTICOID RECEPTOR ANTAGONIST; KETOCONAZOLE; LITHIUM; METYRAPONE; MIFEPRISTONE; MIRTAZAPINE; NOMIFENSINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; ROPINDOLE; S 33005; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P ANTAGONIST; TACHYKININ DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VASOPRESSIN ANTAGONIST;

ATAXIA; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPOMANIA; IMPULSE CONTROL DISORDER; INSOMNIA; MAJOR DEPRESSION; MANIA; NAUSEA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; REVIEW; RHINITIS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING; XEROSTOMIA; ANIMAL; PSYCHIATRY;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHIATRY;

EID: 33847335568     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.2.203     Document Type: Review

References (96)

1. Nemeroff CB, Owens MJ. Treatment of mood disorders. Nat. Neurosci. 2(Suppl.), 1068-1070 (2002). • Similar but briefer overview of the treatment of depression to that of the current paper with a focus on the neurotropic and hypothalamic-pituitary-adrenal axis hypotheses of depression.
2. Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr. Pharmaceut. Design 11, 145-155(2005). •• Detailed focus on the evidence for the neurotropic hypothesis of depression reviewing mostly preclinical data.
3. Wong DT. Duloxetine (LY248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Exp. Opin. Invest. Drugs 7, 1-9 (1998).
4. Kasamo K, Blier P, de Montigny C. Blockade of serotonin and norepininephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J. Pharm. Exp. Ther. 277, 278-286 (1996).
5. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropharmacol. 25, 871-880 (2001).
6. Engleman ES, Perry KW, Mayle DA, Wong DT. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropharmacol. 12, 287-295 (1995).
7. Turcotte JE, Debonnel G, de Montigny C, Herbert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropharmacol. 24, 511-521 (2001).
8. Vincent S, Bieck PR, Garland EM et al. Clinical assessment of norepinephrine transporter blockade throughy biochemical and pharmacological profiles. Circulation 109, 3202-3207 (2004).
9. Berk M, Du Pleiss AD, Birkett M et al. An open label study of duloxetine hydrochloride, a mixed 5-HT and noradrenaline re-uptake inhibitor, in patients with major depressive disorder. Int. Clin. Psychopharmacol. 12, 137-140 (1997).
10. Goldstein DJ, Mallinckrodt CH, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J. Clin. Psychiat. 63, 225-231 (2002).
11. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60mg once daily for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiat. 63, 308-315 (2002).
12. Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine, 60 mg once daily dosing versus placebo in the acute management of major depression. J. Psychiat. Res. 36, 383-390 (2002).
13. Goldstein DJ, Lu Y, Detke MJ. Duloxetine in the treatment of depression. A double-blind placebo-controlled comparison with paroxetine. J. Clin. Psychopharmacol. 24, 389-399 (2004).
14. Detke MJ, Wiltse CG, Mallinckrodt CH et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. NeuroPsychopharmacol. 14, 457-470 (2004).
15. Burt V, Wohlreich MM, Mallinckrodt CH et al. Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics 46, 345-354 (2005).
16. Raskin J, Goldstein DJ, Mallinckrodt CH et al. Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiat. 64, 1237-1244 (2003).
17. Hudson JI, Wohlreich MM, Kajdasz DK. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Human Psychopharmacol. 20, 327-341 (2005).
18. Depreux P, Lesieur D, Mansour HA et al. Synthesis and structure-activity relationships of novel naphthalenic and bioisoteric related amidic derivatives as melatonin receptor ligands. J. Med. Chem. 37, 3231-3239 (1994).
19. Yous S, Andrieux J, Howell HE et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J. Med. Chem. 35, 1484-1486 (1992).
20. Conway S, Canning SJ, Howell E et al. Characterization of human melatonin Mt1 and MT2 receptors by CRE-luciferase reporter assay. Eur. J. Pharmacol. 390, 15-24 (2000).
21. Redman JR, Guardiola-Lemaitre B, BrownM, Delagrange P, Armstrong SM. Dose-dependent effects of S20098, a melatonin agonist on direction of reentrainment of rat circadian rhythms. Psychopharmacol 118, 385-390 (1995).
22. Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome. Pharmacol. Biochem. Behav. 46, 45-49 (1993).
23. Chagraoui A, Protais P, Filloux T, Mocaer E. Agomelatine (S20098) antagonizes the penile erections induced by the stimulation of 5HT2C receptors in Wistar rats. Psychopharmacol. 170, 17-22 (2003).
24. Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharm. Exp. Ther. 306, 954-964 (2003).
25. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J. Psychiat. Neurosci. 29, 126-133 (2004).
26. Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. NeuroPsychopharmacol. 28, 694-703 (2003).
27. Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melanotergic and serotonergic properties: role of 5HT2C receptor blockade Psychopharmacol 177, 1-12 (2005).
28. Loo H, Dalery J, Macher JP, Payen A. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin agonist and selective 5HT2C receptor antagonist, in the treatment of major depressive disorders. L'Encephale 29, 165-171 (2003).
29. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5HT2C antagonist, in the treatment of major depressive disorder: a placebo controlled dose range study. Int. Clin. Psychopharmacol. 17, 239-247 (2002).
30. Montgomery SA, Kennedy SH, Burrows GD, Leyoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled, discontinuation study. Int. Clin. Psychopharmacol. 19, 271-280 (2004)
31. Quera-Salva MA, Vanier B, Chapotot F. Effect of agomelatine on the sleep EEG in patients with major depressive disorders (MDD). Eur. NeuroPsychopharmacol. 15(Suppl. 3), S435 (2005).
32. Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int. Clin. Psychopharmacol. 21(Suppl. 1), S25-S29 (2006).
33. Rogoz Z, Skuza G, Kllodzinska A. Anxiolytic and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 agonist, in rats. Pol. J. Pharmacol. 56, 519-526 (2004).
34. Corrigan MH, Denahan AQ, Wright CE et al. Comparison of pramipexole, fluoxetine and placebo in patients with major depression. Depress. Anxiety 11, 58-65 (2000).
35. Zarate CA, Payne JL, Singh J et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry. 56, 54-60 (2004).
36. Sporn J, Ghaemi SN, Sambur MR et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann. Clin. Psychiatry 12, 137-140 (2000).
37. Perugi G, Toni C, Ruffolo G et al. Adjunctive dopamine agonists in treatment - resistant bipolar-II depression: an open case series. Pharmacopsychiatry 34, 137-141 (2001).
38. Lattanzi L, Dell'Osso L, Cassano P et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 4, 307-314 (2002).
39. Cassano P, Lattanzi L, Soldani F et al. Pramipexole in treatment resistant depression an extended follow-up. Depress. Anxiety 20, 131-138 (2004).
40. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress. Anxiety 7(Suppl. 1) 11-17 (1998). • Meta-analysis presenting the case that tricyclic antidepressants may be more efficacious in the treatment of certain forms of major depression than selective serotonin-reuptake inhibitors (SSRIs).
41. Gupta RK, Tiller JWG, Burrows GD. Dual action antidpressants and some important considerations. Aust. NZ J. Psychiat. 37, 190-195 (2003).
42. Briley M. New hope in the treatment of painful symptoms in depression. Curr. Opin. Invest. Drugs 4, 42-45 (2003).
43. DeBoer T, Nefkens F, van Helvoirt A. The α2-adrenoceptor antagonist Org3770 enhances noradrenergic and 5HT1A mediated serotonergic neurotransmission in vivo. Eur. J. Pharmacol. 253, R5-R6 (1994).
44. Olver JS, Burrows GD, Norman TR. Third generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 15, 941-954 (2001). • Qualitative review of data comparing newer antidepressants with the SSRIs, suggesting that the newest antidepressants are only equal in efficacy to the SSRIs with respect to onset of action, side effects and safety.
45. Millan MJ, Gobert A, Lejeune F et al. S33005, a novel ligand at both serotonin and norepinephrine transporters I: receptor binding, electrophysiological and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram and clomipramine. J. Pharm. Exp. Ther. 298, 565-580 (2001).
46. Millan MJ, Dekeyne A, Papp M et al. S33005, a novel ligand at both serotonin and norepinephrine transporters II: behavioral profile in comparison with venlafaxine, reboxetine, citalopram and clomipramine. J. Pharm. Exp. Ther. 298, 581-591 (2001).
47. Cespuglio R, Rousset C, Debilly G et al. Acute administration of the novel serotonin and noradrenaline reuptake inhibitor S33005, markedly modifies sleep-wake cycle architecture in the rat. Psychopharmacol. 181, 639-652 (2005).
48. Board F, Persky H, Hamburg DA. Psychological stress and endocrine functions, Psychosomaticsic Med. 18, 324-333 (1956).
49. Gibbons JL. Cortisol secretion rate in depressive illness. Arch. Gen. Psychiat. 10, 572-575 (1964).
50. Mitchell P, Hadzi-Pavlovic D, Parker G et al. Depressive psychomotor disturbance, cortisol and dexamethasone. Biol. Psychiat. 40, 941-950 (1996).
51. Arborelius L, Owens MJ, Plotsky PM et al. The role of corticotrophin releasing factor in depression and anxiety disorders. J. Endocrinol. 160, 1-12 (1999).
52. Deuschle M, Schweiger U, Weber B et al. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J. Clin. Endocrinol. Metab. 82, 234-238 (1997).
53. Nemeroff CB, Widerlov E, Bisette G et al. Elevated concentrations of CSF corticotrophin releasing factor-like immunoreactivity in depressed patients. Science 226, 1342-1344 (1984).
54. McQuade R, Young AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br. J. Psychiat. 177, 390-395 (2000).
55. Ravaris CL, Sateia MJ, Beroza KW et al. Effect of ketoconazole on a hypophysectomised, hypercortisolaemic, psychotically depressed woman. Arch. Gen. Psychiat. 45, 966-967 (1988).
56. Murphy BE. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 22(Suppl. 1), S125-S132 (1997).
57. Wolkowitz OM, Reus VI, Chan T et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol. Psychiat. 45, 1070-1074 (1999).
58. Malison RT, Anand A, Pelton GH et al. Limited efficacy of ketoconazole in treatment refractory major depression. J. Clin. Psychiat. 19, 466-470 (1999).
59. Murphy BE, Filipini D, Ghadirian AM. Possible use of the glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU486. J. Psychiat. Neurosci. 18, 209-213 (1993).
60. Belanoff JK, Flores BH, Kalezhan M et al. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21, 516-521 (2001).
61. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat. Med. 7, 605-611 (2001).
62. Gilligan PJ, Robertson DW, Zaczek R. Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem. 43, 1641-1660 (2000). •• Review of the medicinal chemistry of drugs acting at corticotropin-releasing factor receptors, and an exploration of their potential for the treatment of depression and anxiety.
63. Lelas S, Wong H, Li Y-W et al. Anxiolytic-like effects of the corticotrophin- releasing factor 1 (CRF1) antagonist DMP904 [4-(3-pentylamino)- 2,7-dimethyl- 8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. J. Pharm. Exp. Ther. 309, 293-302 (2004).
64. Mansbach RS, Brooks EN, Chen YL. Antidepressant-like effects of CP-154,526, a selective CRF1 antagonist. Eur. J. Pharmacol. 323, 21-26 (1997).
65. Arborelius L, Skelton KH, Thrivikraman KV et al. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. J. Pharm. Exp. Ther. 294, 588-597 (2000).
66. Hoyberg J, Wik G, Mehtonen OP et al. ORG 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: first clinical results. Int. J. NeuroPsychopharmacol. 5(Suppl. 1), 148 (2002).
67. Zobel AW, Nickel T, Kunzel HEM. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiat. Res. 34, 171-181 (2000).
68. Rupniak N, Kramer MS. Substance P and related tachykinins. In: Neuropsychopharmacology The Fifth Generation of Progress. Davis KL, Charney D, Coyle JT, Nemeroff CB (Eds). American College of Neuropsychopharmacology 171-177 (2002).
69. Mantyh PD. Neurobiology of substance P and the NK1 receptor. J. Clin. Psychiat. 63(Suppl. 1), 6-10 (2002).
70. Kramer MS, Cutler N, Feighner J et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640-1645 (1998).
71. Krishnan KRR. Clinical experience with substance P receptor (NK1) antagonists in depression. J. Clin. Psychiat. 63(Suppl. 1), 25-29 (2002).
72. Gold PW, Goodwin FK, Reus VI. Vasopressin in affective illness. Lancet 1, 1233-1236 (1978).
73. van Louden L, Goekoop JG, van Kempen GM et al. Plasma levels of arginine vasopressin elevated in patients with major depression, NeuroPsychopharmacol. 17, 284-292 (1997).
74. de Winter RF, van Hemert AM, DeRijk RH et al. Anxious-retarded depression: relation to plasma vasopressin and cortisol. NeuroPsychopharmacol. 28, 140-147 (2003).
75. De Bellis MD, Gold PW, Geracioti TD et al. Association of fluoxetine treatment with reductions in CSF concentrations of corticotrophin-releasing hormone and arginine vasopressin in patients with major depression. Am. J. Psychiat. 150, 656-657 (1993).
76. Ring RH. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr. Pharm. Des. 11, 205-225 (2005). •• Detailed review of the potential for compounds that interact with the vasopressin system to act as antidepressants. More detailed review of data presented in this article.
77. Ebner K, Wotjak CT, Holsboer F et al. Vasopressin released within the septal brain area during swim stress modulates the behavioural stress response in rats. Eur. J. Neurosci. 11, 997-1002 (1999).
78. EbnerK, Wotjak CT, Landgraf R et al. Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats, Eur. J. Neurosci. 15, 384-388 (2002).
79. Serradeil-Le Gal C, Derick S, Brossard G et al. Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. Stress 6, 199-206 (2003).
80. Tanoue A, Ito S, Honda K et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J. Clin. Invest. 113, 302-309 (2004).
81. Griebel G, Simiand J, Stemmelin J et al. The vasopressin V1b receptor as a therapeutic target in stress related-related disorders. Curr. Drug Target CNS Neurol. Disord. 2, 191-200 (2003).
82. Griebel G, Simiand J, Serradeil-Le Gal C et al. Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist SSR149415 suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl Acad. Sci. USA 99, 6370-6375 (2002).
83. Nowak G, Trullas R, Layer RT et al. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocycloprpane carboxylic acid. J. Pharm. Exp. Ther. 265, 1380-1386 (1993).
84. Paul IA, Layer RT, Skolnick P et al. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur. J. Pharmacol. 247, 305-311 (1993).
85. Skolnick P. Antidepressants for the new millennium. Eur. J. Pharmacol. 375, 31-40 (1999).
86. Skolnick P. Modulation of glutamate receptors: strategies for the development of novel antidepressants. Amino Acids 23, 153-159 (2002). •• Material canvassed in the present review is also presented in this article.
87. Pacher P, Kecskemeti V. Trends in the development of new antidepressants: is there light at the end of the tunnel? Curr. Med. Chem. 11, 925-943 (2004).
88. Redrobe JP, Dumont Y, Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci. 71, 2921-2937 (2002).
89. Stogner KA, Holmes PV. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur. J. Pharmacol. 387, R9-R10 (2000).
90. Qu D. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 380, 243-247 (1996).
91. Sato Y. Molecular characterization of the melanin-concentrating-hormone receptor. Nature 400, 265-269 (1999).
92. Borowsky B, Durkin MM, Ogozalek K et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat. Med. 8, 825-830 (2002).
93. Duman RS. Depression: a case of neuronal life and death? Biol. Psychiat. 56, 140-145 (2004). •• Draws together the preclinical and clinical evidence for the neurogenesis hypothesis of depression.
94. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Rev. 45, 104-114 (2004).
95. Shirayama Y, Chen ACH, Nakagawa DS et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioural models of depression. J. Neurosci. 22, 3251-3261 (2002).
96. Siuciak JA, Lewis DR, Wiegand RM et al. Antidepressant like effect of brain derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 56, 131-137 (1997).